Shrinkage of pegylated and non-pegylated liposomes in serum
about
Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and UsesSafety of Nanoparticles in MedicineBiomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery.The nano-plasma interface: Implications of the protein corona.Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.Multistage vector (MSV) therapeutics.Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.Recent advances in characterization of nonviral vectors for delivery of nucleic acids: impact on their biological performance.Functional liposomes in the cancer-targeted drug delivery.Effects of the protein corona on liposome-liposome and liposome-cell interactions.Strategies for improving drug delivery: nanocarriers and microenvironmental priming.Investigations on agglomeration and haemocompatibility of vitamin E TPGS surface modified berberine chloride nanoparticlesA Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.In situ detection of the protein corona in complex environments.Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity.Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles.Temperature-sensitive liposomal ciprofloxacin for the treatment of biofilm on infected metal implants using alternating magnetic fields.Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles.
P2860
Q28071773-D8539EC4-9B91-45CD-AD75-EF54BB4CE27DQ28083076-DD7EDA04-7978-41EB-88D8-2268389F6CF6Q30369753-6C42BC07-BA83-4A21-9FBD-90A4ED161C90Q34122883-94909D0B-2867-4F99-B37A-FD1131B87F5EQ34502573-99DD9AF3-D341-4C31-8F19-6F76718C0437Q36307634-186D8DA2-B213-4368-9809-7C6D9379F556Q36334131-5908CFA8-3B08-42F9-B6D2-FDD95A0E4715Q38241667-76F27D97-D4DE-4F61-A948-8A363F598CE1Q38396298-B55E6DA8-BAD5-44AC-882A-39E391758B48Q38756510-CB707697-A2E2-4BE6-8D0D-98163C7AD25DQ38968910-3FAD39D2-6231-4561-A14B-F965D2540EADQ41968953-64EF6E1F-C204-4FB9-BDE9-E9631BD9B7CAQ42972230-9A3C825B-E437-4874-B330-FBD457BC6FD7Q47165423-4C7A7D76-879B-492D-9F3F-AF51DB162226Q47199315-74B90A87-FC84-4E2B-A03F-D6F73DC51E67Q50921061-E1B0EE74-831A-4CD7-BDB9-D74A202A6C40Q51745320-828CF5D3-7022-4E62-8D19-47BE7B67D4EAQ53154282-03CDBCE0-EDA5-47E5-AC76-8C9E9523BD6B
P2860
Shrinkage of pegylated and non-pegylated liposomes in serum
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Shrinkage of pegylated and non-pegylated liposomes in serum
@en
Shrinkage of pegylated and non-pegylated liposomes in serum.
@nl
type
label
Shrinkage of pegylated and non-pegylated liposomes in serum
@en
Shrinkage of pegylated and non-pegylated liposomes in serum.
@nl
prefLabel
Shrinkage of pegylated and non-pegylated liposomes in serum
@en
Shrinkage of pegylated and non-pegylated liposomes in serum.
@nl
P2093
P2860
P1476
Shrinkage of pegylated and non-pegylated liposomes in serum
@en
P2093
Christian Celia
Haifa Shen
Jianliang Shen
Krishna Suri
Mauro Ferrari
Yuliang Zhao
P2860
P304
P356
10.1016/J.COLSURFB.2013.10.009
P577
2013-10-24T00:00:00Z